Bifidobacterium longum W11 (LMG P-21586)

1) Amenta M. et al. Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight). Acta Biomed 2006; 77(3):157-62.

2) Colecchia A. et al. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol 2006; 52(4):349-58.

3) Fanigliulo L. et al. Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Biomed 2006; 77(2):85-9.

4) Sarnelli G. et al. Effects of oral supplementation with the symbiotic (Bifidobacterium longum W11 + FOS Actilight) on IBS with constipation: a randomized, dose finding trial, versus fibers. Digestive and Liver Disease 2008; 40(1):S141.

5) Malaguarnera M. et al. Bifidobacterium longum with fructooligosaccharides (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007; 52:3259-3265.  Doi: 10.1007/s10620-006-9687-y

6) Dughera L. et al. Effects of symbiotic preparation on constipated irritable bowel syndrome symptoms. Acta Biomed 2007; 78:111-116.

7) Del Piano M. et al. Clinical Experience With Probiotics in the Elderly on Total Enteral Nutrition. J Clin Gastroenterol 2004;38:S111-S114. Doi: 10.1097/01.mcg.0000128937.32835.7c

8) Di Pierro F. et al. Effects of rifaximin-resistant Bifidobacterium longum W11 in subjects with symptomatic uncomplicated diverticular disease treated with rifaximin. Minerva Gastroenterol Dietol. 2019 Dec; 65(4):259-264. Doi: 10.23736/S1121-421X.19.02622-9

a) Graziano T. et al. The possible innovative use of Bifidobacterium longum W11 in association with rifaximin: a new horizon for combined approach? J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S153-S156.

b) Inturri R. et al. Complete Genome Sequence of Bifidobacterium longum W11 (LMG P-21586), Used as a Probiotic Strain. Genome Announc. 2017 Mar 9;5(10). pii: e01659-16. doi: 10.1128/genome A.01659-16.

c) Inturri R. et al. Chemical and biological properties of the novel exopolysaccharide produced by a probiotic strain of Bifidobacterium longum. Carbohydr Polym. 2017 Oct 15;174:1172-1180. doi: 10.1016/j.carbpol.2017.07.039. 

d) Medina et al. Differential immunomodulatory properties of Bifidobacterium logum strains: relevance to probiotic selection and clinical applications. Clin Exp Immunol. 2007 Dec;150(3):531-8. doi: 10.1111/j.1365-2249.2007.03522.x. 

e) Izquierdo E. et al. Resistance to Simulated Gastrointestinal Conditions and Adhesion to Mucus as Probiotic Criteria for B. longum strains. Curr Microbiol 2008, 56:613-618. doi:10.1007/s00284-008-9135-7

f) Interri R. et al. Scanning Electro Microscopy Observation of Adhesion Properties of B. longum W11 and Chromatographic Analysis of Its Exopolysaccharide.  Food and Nutrition Sciences 2014,  1787-1792. doi:10.4236/fns.2014.518192 

g) Interri R. et al.  Immunomodulatory Effects of Bifidobacterium longum W11 Produced Exopolysaccharide on Cytokine Production. Curr Pharm Biotechnol. 2017;18(11):883-889. doi: 10.2174/1389201019666171226151551. 

h) B. longum W11, an antibiotic resistant probiotic, Di Pierro 2018, CEC online article: https://www.nutrafoods.eu/index.php/nutra/article/view/93

1) Malaguarnera M. et al. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci. 2007 Nov;52(11):3259-65. doi: 10.1007/s10620-006-9687-y.